StockData

Alpha Cognition vs LENZ Therapeutics

ACOG and LENZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACOG and LENZ compare

Alpha Cognition is the larger company, worth 1.4 times as much as LENZ Therapeutics ($171M against $120M).

Alpha Cognition keeps more of each dollar of sales as profit, with a net margin of −154% compared with −587% at LENZ Therapeutics.

LENZ Therapeutics scores higher on the StockData Score (9 against 7 for Alpha Cognition), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACOGLENZ
Size and price
Market cap$171M$120M
Share price$7.83$3.82
Change, 1 year27.7%−85.6%
Change, 5 years−63.2%−94.3%
Beta (5Y)2.492.15
Employees72152
StockData Score
Total score79 (better)
Valuation score03 (better)
Growth score01 (better)
Performance score1 (better)0
Health score6 (better)5
Dividend score00
Valuation
P/S11.2×5.6× (better)
P/B3.2×0.5× (better)
FCF yield−18.3% (better)−95.3%
Fair value$4.89$7.83
Margin of safety−60.2%51.2% (better)
Growth
Revenue growth (TTM)–330%
Profitability
Gross margin92.7%–
Operating margin−191% (better)−632%
Net margin−154% (better)−587%
FCF margin−204% (better)−533%
Return on equity−58.8% (better)−59.2%
Financial health
Debt / equity0.000.00
Current ratio9.0313.55 (better)
Altman Z-score6.12 (better)1.67
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions48.7%110%
Held by insiders5.1%6.7%
Insider net buying, 12 months$8.3M (better)−$8.8M
Short interest, % of float2.0%24.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.